Silo Pharma Inc. (NASDAQ: SILO) announced that its board of directors has authorized a share repurchase program allowing the company to acquire up to $1 million of its common stock. The program, which takes effect immediately, permits purchases through open market transactions, privately negotiated deals, or other methods, all in compliance with Securities and Exchange Commission rules and applicable legal requirements. The company reported 13,318,273 shares of common stock outstanding as of November 13, 2025, according to its quarterly report for the period ended September 30, 2025.
The timing and amount of any repurchases will depend on market conditions, corporate considerations, and regulatory limitations. The program does not obligate Silo Pharma to acquire a specific number of shares and may be suspended or discontinued at the company's discretion. This move comes as a signal of management's confidence in the company's intrinsic value and its commitment to enhancing shareholder value.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories.
The share repurchase program may provide a floor for the stock price and could be viewed as a positive signal by investors, especially given the volatile nature of the biopharmaceutical sector. However, the company's status as a developmental-stage firm means it has yet to generate revenue from product sales, and its cash position is critical for funding ongoing research and development activities.
For more information, the full press release is available at https://ibn.fm/gU3uZ. The latest news and updates relating to SILO can be found in the company's newsroom at https://ibn.fm/SILO.
